Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus PEPCID RPD.
PEPCID AC vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist